Skip to content

Study · Randomized controlled trial · n = 9 · 2023

7 results

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.

Kubota M, Yamamoto K, Yoshiyama S

Cureus4 Oct 2023Cited by 15 (Europe PMC)

PMID37800161 (opens in a new tab)PMCIDPMC10550307 (opens in a new tab)DOI10.7759/cureus.46490 (opens in a new tab)PepBankPUB-37800161
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Introduction The purpose of this study was to examine changes in blood glucose levels and body weight after discontinuation of tirzepatide, a novel long-acting dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included. Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group. Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group. At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups. Furthermore, in the tirzepatide groups, dose-dependent weight regain was observed from an early stage. Conclusions Compared to dulaglutide, tirzepatide exhibited excellent blood-glucose-improving and weight-reducing effects. However, exacerbation of blood glucose and rebound of weight gain occurred relatively early after administration was ended. For type 2 diabetes patients who need weight loss and are prescribed tirzepatide, these findings suggest a necessity for continuous prescription or careful follow-up when stopping.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, HbA1c improvement was smaller with dulaglutide than in all tirzepatide groups.

    In plain wordsIn patients with diabetes, dulaglutide improved HbA1c less than tirzepatide during treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c during treatment
    Study

    n = 9

    Comparator
    Tirzepatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes, body weight improvement was smaller with dulaglutide than in all tirzepatide groups.

    In plain wordsIn patients with diabetes, dulaglutide improved body weight less than tirzepatide during treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseBody weight during treatment
    Study

    n = 9

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.75 mg · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.
  3. 03HumanCase report or seriesEfficacy outcome

    In patients with diabetes, all tirzepatide groups had improved HbA1c compared with dulaglutide after treatment.

    In plain wordsIn patients with diabetes, tirzepatide improved HbA1c more than dulaglutide during treatment.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c during treatment
    Study

    n = 9

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5 mg, 10 mg or 15 mg · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.
  4. 04HumanCase report or seriesEfficacy outcome

    In patients with diabetes, all tirzepatide groups had improved body weight compared with dulaglutide.

    In plain wordsIn patients with diabetes, tirzepatide improved body weight more than dulaglutide during treatment.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight during treatment
    Study

    n = 9

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5 mg, 10 mg or 15 mg · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In patients with diabetes, HbA1c rose after tirzepatide withdrawal, as it did in all study groups.

    In plain wordsIn patients with diabetes, HbA1c rose after tirzepatide stopped, as in all groups.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHbA1c after withdrawal
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 06HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In patients with diabetes, HbA1c rose after dulaglutide withdrawal, as it did in all study groups.

    In plain wordsIn patients with diabetes, HbA1c rose after dulaglutide stopped, as in all groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c after withdrawal
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At two, four, and six months after the end of study drug administration, re-elevation of HbA1c was observed in all groups.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 07HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In patients with diabetes, early dose-dependent weight regain occurred after tirzepatide withdrawal.

    In plain wordsIn patients with diabetes, weight returned early after tirzepatide stopped, with a dose-dependent pattern.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight regain after withdrawal
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Furthermore, in the tirzepatide groups, dose-dependent weight regain was observed from an early stage.
    4 context sentences
    Summary · context
    Methods Nine subjects (five males, four females, age 54.3±5.4 years, body mass index 33.5±3.3 kg/m2) participating with type 2 diabetes in the SURPASS J-mono study were included.
    Summary · context
    Subjects were randomized to tirzepatide 5 mg, 10 mg, 15 mg, or a dulaglutide 0.75 mg group.
    Summary · context
    Fifty-two weeks after randomization, study drug administration was discontinued.
    Summary · context
    To investigate progress after the end of administration, changes in hemoglobin A1c (HbA1c) and body weight were further examined two, four, and six months after discontinuation of the study drug.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.